Discover a Competitive Edge: 3 Reasons Supply Chain Executives outside Pharmaceutical Should Pay Attention to the DSCSA 2023 November Deadline.

The pharmaceutical supply chain will turn on end-to-end traceability in November this year. It’s a big undertaking with many challenges still ahead. These challenges stem from serializing each sellable unit from the point of manufacture to the patient. And being able to track thru the supply chain. It’s a daunting task, but the benefits are clear. When implemented, manufacturers will gain visibility into their downstream supply chains. There will be many benefits. Including helping them avoid stockouts and excess inventory and to identify sources of counterfeits. 1) Real-world proof points that show how serialization can benefit the entire value chain. And key areas for potential investment. 2) Successful implementations will stress-test key technology. Pharmaceutical Supply Chains are complex, with large and small manufacturers and suppliers collaborating globally. Surviving technologies will have been stress tested at scale. 3) Understanding the resulting collaboration processes built upon the technology. Many supply chains are multienterprise systems that need processes that support the teams. 4) BONUS — your teams need something other than Microsoft Excel and Email to be successful in 2023. So reach out to your contacts in Pharmaceutical Manufacturing, say Happy New Year and offer to buy them dinner. They have a great deal of groundbreaking work to do this year. By year-end, successful companies will have supply chains with exceptional traceability.

#supplychain #collaboration #serialization #technology